Evidence map›Paper›PMID 28387632›Full record

ArticleJournal of neurosurgery2018

Near-infrared fluorescent image-guided surgery for intracranial meningioma.

John Y K Lee, John T Pierce, Jayesh P Thawani, Ryan Zeh, Shuming Nie, Maria Martinez-Lage, Sunil Singhal

Registry-linked trialOpen access · bronzeAbstract read
In one paragraph

Article in Journal of neurosurgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02280954 (A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02280954 phase1completednot on this map

A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green

TypeinterventionalSponsorUniversity of PennsylvaniaRan2013 to 2017Enrolled48ConditionsSolid Tumor, NeoplasmsArmsIndocyanine Green (ICG)
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 82 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Image-Guided Brain Tumor Surgery.Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer · 2026
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Next-generation agents for fluorescence-guided glioblastoma surgery.Bioengineering & translational medicine · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

John Y K LeeDepartments of1Neurosurgery.
John T PierceDepartments of1Neurosurgery.
Jayesh P ThawaniDepartments of1Neurosurgery.
Ryan ZehDepartments of1Neurosurgery.
Shuming Nie5Department of Chemistry, Emory University School of Medicine, Atlanta,Georgia.
Maria Martinez-Lage3Pathology, Hospital of the University of Pennsylvania.
Sunil Singhal2Surgery, and.
University of Pennsylvania · USEmory University · USHospital of the University of Pennsylvania · US

Funding

Institutional Clinical and Translational Science AwardUL1TR000003 · NCATS · UNIVERSITY OF PENNSYLVANIA · PI FITZGERALD, GARRET A · 2012 to 2015
$38.9M
Near infrared intraoperative molecular imaging of lung adenocarcinomaR01CA193556 · NCI · UNIVERSITY OF PENNSYLVANIA · PI LOW, PHILIP STEWART, SINGHAL, SUNIL · 2016 to 2020
$3.3M
NCATS NIH HHS UL1 TR000003NCI NIH HHS R01 CA193556
6 · The paper itself

Abstract

OBJECTIVE Meningiomas are the most common primary tumor of the central nervous system. Complete resection can be curative, but intraoperative identification of dural tails and tumor remnants poses a clinical challenge. Given data from preclinical studies and previous clinical trials, the authors propose a novel method of localizing tumor tissue and identifying residual disease at the margins via preoperative systemic injection of a near-infrared (NIR) fluorescent contrast dye. This technique, what the authors call "second-window indocyanine green" (ICG), relies on the visualization of ICG approximately 24 hours after intravenous injection. METHODS Eighteen patients were prospectively identified and received 5 mg/kg of second-window ICG the day prior to surgery. An NIR camera was used to localize the tumor prior to resection and to inspect the margins following standard resection. The signal to background ratio (SBR) of the tumor to the normal brain parenchyma was measured in triplicate. Gross tumor and margin specimens were qualitatively reported with respect to fluorescence. Neuropathological diagnosis served as the reference gold standard to calculate the sensitivity and specificity of the imaging technique. RESULTS Eighteen patients harbored 15 WHO Grade I and 3 WHO Grade II meningiomas. Near-infrared visualization during surgery ranged from 18 to 28 hours (mean 23 hours) following second-window ICG infusion. Fourteen of the 18 tumors demonstrated a markedly elevated SBR of 5.6 ± 1.7 as compared with adjacent brain parenchyma. Four of the 18 patients showed an inverse pattern of NIR signal, that is, stronger in the adjacent normal brain than in the tumor (SBR 0.31 ± 0.1). The best predictor of inversion was time from injection, as the patients who were imaged earlier were more likely to demonstrate an appropriate SBR. The second-window ICG technique demonstrated a sensitivity of 96.4%, specificity of 38.9%, positive predictive value of 71.1%, and a negative predictive value of 87.5% for tumor. CONCLUSIONS Systemic injection of NIR second-window ICG the day before surgery can be used to visualize meningiomas intraoperatively. Intraoperative NIR imaging provides higher sensitivity in identifying meningiomas than the unassisted eye. In this study, 14 of the 18 patients with meningioma demonstrated a strong SBR compared with adjacent brain. In the future, reducing the time interval from dye injection to intraoperative imaging may improve fluorescence at the margins, though this approach requires further investigation. Clinical trial registration no.: NCT02280954 ( clincialtrials.gov ).

Indexed as

AdultAgedCohort StudiesColoring AgentsFemaleHumansImmunohistochemistryIndocyanine GreenMaleMargins of ExcisionMeningeal NeoplasmsMeningiomaMiddle AgedNeurosurgical ProceduresOptical ImagingProspective StudiesColoring AgentsIndocyanine Green125IR5-ALA = 5-aminolevulinic acidbrain tumorEPR = enhanced permeability and retentionfluorescenceICG = indocyanine greenindocyanine greenmeningiomanear infraredNIR = near-infrared dyeNPV = negative predictive valueoncologyPPV = positive predictive valueROC = receiver operating characteristicSBR = signal to background ratio

Identifiers

PMID28387632
PMCPMC10985532
OpenAlexW2604780455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.